Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

NCT06005012 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can reduce liver scarring (fibrosis) in people with obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD).

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 120 people Planned (estimated).

Who can join Ages 40–79 · all sexes

Timeline Started 2023-07 · est. completion 2025-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06005012 ↗

Description as written by the study sponsor.

Conduct a community intervention study that will 1) validate a screening approach to identify patients at risk for advanced NAFLD in the obese or T2DM population, and 2) test whether semaglutide treatment is effective for the management of significant fibrosis due to NAFLD in high-risk patients.

Treatments tested

Semaglutide Drug

Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).
Placebo Drug

Placebo

Main thing measured	Change in fibrosis due to NAFLD
Sponsor	University of California, San Diego
Conditions studied	Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06005012 ↗